Federal Register / Vol. 72, No. 195 / Wednesday, October 10, 2007 / Notices 57577 

1. Standard Chartered PLC, Standard 

Chartered Holdings Limited, and 

Standard Chartered Bank, all of 

London, United Kingdom; to acquire 

Harrison Lovegrove & Co. Limited, 

London, England, and thereby indirectly 

acquire Harrison Lovegrove Americas 

L.P., Houston, Texas, and thereby 

engage in providing advice in 

connection with mergers, acquisitions, 

divestitures, investments, joint ventures, 

leveraged buyouts, recapitalizations, 

capital structurings, financing 

transactions and similar transactions, 

and conducting financial feasibility 

studies in accordance with Section 

225.28(b)(6)(iii); and acting as agent for 

the private placement of securities, 

pursuant to Section 225.28(b)(7)(iii), 

both of Regulation Y. 

B. Federal Reserve Bank of Chicago 

(Burl Thornton, Assistant Vice 

President) 230 South LaSalle Street, 

Chicago, Illinois 60690–1414: 

1. Capitol Bancorp, Ltd., and Capitol 

Development Bancorp Limited VIII, both 

of Lansing, Michigan; to acquire 51 

percent of the voting shares of 

Community Bank of Lincoln (in 

organization), Lincoln, Nebraska, and 

thereby operate a savings association, 

pursuant to section 225.28(b)(4)(ii) of 

Regulation Y. Comment on this 

application must be received by 

November 5, 2007. 

Board of Governors of the Federal Reserve 

System, October 4, 2007. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. E7–19921 Filed 10–9–07; 8:45 am] 

BILLING CODE 6210–01–S 

FEDERAL RESERVE SYSTEM 

Consumer Advisory Council 

ACTION: Notice of Meeting of the 

Consumer Advisory Council 

The Consumer Advisory Council will 

meet on Thursday, October 25, 2007. 

The meeting, which will be open to 

public observation, will take place at the 

Federal Reserve Board’s offices in 

Washington, DC., in Dining Room E on 

the Terrace Level of the Martin 

Building. Anyone planning to attend the 

meeting should, for security purposes, 

register no later than Tuesday, October 

23, by completing the form found online 

at: https://www.federalreserve.gov/ 

secure/forms/cacregistration.cfm 

Additionally, attendees must present 

photo identification to enter the 

building. 

The meeting will begin at 9 a.m. and 

is expected to conclude at 1 p.m. The 

Martin Building is located on C Street, 

NW., between 20th and 21st Streets. 

The Council’s function is to advise 

the Board on the exercise of the Board’s 

responsibilities under various consumer 

financial services laws and on other 

matters on which the Board seeks its 

advice. Time permitting, the Council 

will discuss the following topics: 

• Home Ownership and Equity 

Protection Act (HOEPA) 

Members will discuss various issues 

related to the Board’s rulemaking 

authority under HOEPA to address 

concerns about abusive lending 

practices in the home mortgage market. 

• Regulation Z/Truth in Lending Act 

(TILA) 

Members will discuss issues that have 

been raised in public comments on the 

proposed amendments to Regulation Z, 

which implements the Truth in Lending 

Act (TILA). The amendments would 

revise the disclosure requirements for 

open–end (revolving) plans that are not 

home–secured, including credit2186d 

accounts. 

Reports by committees and other 

matters initiated by Council members 

also may be discussed. 

Persons wishing to submit views to 

the Council on any of the above topics 

may do so by sending written 

statements to Jennifer Kerslake, 

Secretary of the Consumer Advisory 

Council, Division of Consumer and 

Community Affairs, Board of Governors 

of the Federal Reserve System, 

Washington, D.C. 20551. Information 

about this meeting may be obtained 

from Ms. Kerslake, 202–452–6470. 

Board of Governors of the Federal Reserve 

System, October 3, 2007. 

Jennifer J. Johnson, 

Secretary of the Board. 

[FR Doc. E7–19842 Filed 10–9–07; 8:45 am] 

BILLING CODE 6210–01–S 

FEDERAL RESERVE SYSTEM 

Sunshine Act Meeting 

AGENCY HOLDING THE MEETING: Board of 

Governors of the Federal Reserve 

System. 

TIME AND DATE: 11:30 a.m., Monday, 

October 15, 2007. 

PLACE: Marriner S. Eccles Federal 

Reserve Board Building, 20th and C 

Streets, NW., Washington, DC 20551. 

STATUS: Closed. 

MATTERS TO BE CONSIDERED: 

1. Personnel actions (appointments, 

promotions, assignments, 

reassignments, and salary actions) 

involving individual Federal Reserve 

System employees. 

2. Any items carried forward from a 

previously announced meeting. 

FOR FURTHER INFORMATION CONTACT: 

Michelle Smith, Director, or Dave 

Skidmore, Assistant to the Board, Office 

of Board Members at 202–452–2955. 

SUPPLEMENTARY INFORMATION: You may 

call 202–452–3206 beginning at 

approximately 5 p.m. two business days 

before the meeting for a recorded 

announcement of bank and bank 

holding company applications 

scheduled for the meeting; or you may 

contact the Board’s Web site at http:// 

www.federalreserve.gov for an electronic 

announcement that not only lists 

applications, but also indicates 

procedural and other information about 

the meeting. 

Board of Governors of the Federal Reserve 

System, October 5, 2007. 

Robert deV. Frierson, 

Deputy Secretary of the Board. 

[FR Doc. 07–5021 Filed 10–5–07; 2:39 pm] 

BILLING CODE 6210–01–S 

FEDERAL TRADE COMMISSION 

Granting of Request for Early 

Termination of the Waiting Period 

Under the Premerger Notification 

Rules 

Section 7A of the Clayton Act, 15 

U.S.C. 18a, as added by Title II of the 

Hart-Scott-Rodino Antitrust 

Improvements Act of 1976, requires 

persons contemplating certain mergers 

or acquisitions to give the Federal Trade 

Commission and the Assistant Attorney 

General advance notice and to wait 

designated periods before 

consummation of such plans. Section 

7A(b)(2) of the Act permits the agencies, 

in individual cases, to terminate this 

waiting period prior to its expiration 

and requires that notice of this action be 

published in the Federal Register. 

The following transactions were 

granted early termination of the waiting 

period provided by law and the 

premerger notification rules. The grants 

were made by the Federal Trade 

Commission and the Assistant Attorney 

General for the Antitrust Division of the 

Department of Justice. Neither agency 

intends to take any action with respect 

to these proposed acquisitions during 

the applicable waiting period. 


rwilkins on PROD1PC63 with NOTICES
57578 Federal Register / Vol. 72, No. 195 / Wednesday, October 10, 2007 / Notices 

Trans # Acquiring Acquired Entities 

Transactions Granted Early Termination—09/24/2007 

20072076 ......................... UniCredito Italiano S.p.A ................... Capitalia S.p.A ................................... Capitalia S.p.A. 

20072122 ......................... Explorer Pipeline Company ............... Petroleos de Venezuela S.A ............. Petroleos de Venezuela S.A. 

20072129 ......................... Abu Dhabi National Energy Company PJSC.Pioneer Natural Resources Company Pioneer Natural Resources Canada 

Inc. 

20072145 ......................... Great Hill Equity Partners III, L.P ...... Mark Towfiq and Carol Nakahara ..... InteleNet Communications, Inc. 

20072152 ......................... Eugene M. Isenberg .......................... Nabors Industries Ltd ........................ Nabors Industries Ltd. 

20072153 ......................... Energy Transfer Partners, L.P .......... MSCP IV CRDI, LLC ......................... Canyon Gas Resources, LLC 

20072155 ......................... Copano Energy, L.L.C ....................... MSCP IV CRDI, LLC ......................... Cantera Natural Gas, LLC 

Transactions Granted Early Termination—09/25/2007 

20072101 ......................... Infineon Technologies AG ................. LSI Corporation ................................. LSI Corporation 

20072109 ......................... Audax Private Equity Fund II, L.P ..... Bill D. Brady, as Trustee of the Bill 

D. Brady Trust.

Brady Holdings, LLC 

20072136 ......................... S-Process Equipment International 

S.a.r.l.

Schenck Process SA ......................... Schenck Process Holding GmbH 

20072156 ......................... AEGON N.V ...................................... Merrill Lynch & Co., Inc ..................... Merrill Lynch Life Insurance Company, ML Life Insurance Company 

of New York 

20072160 ......................... FleetCor Technologies, Inc ............... Chevron Corporation ......................... Chevron U.S.A. Inc. 

20072163 ......................... J.P. Morgan Chase & Co .................. Sud Chemie AG ................................ Sud Chemie AG 

20072165 ......................... NTR plc ............................................. Edgewater Growth Capital Partners, 

LP.

Recycled Holdings Corporation 

20072167 ......................... Babcock & Brown Limited ................. Bill Sjolander ..................................... CMC Industries, Inc., CMC Railroad, 

Inc. 

20072168 ......................... Lydian Capital Partners LP ............... Trilogy Investors, LLC ....................... Trilogy Investors, LLC 

20072171 ......................... Management Consulting Group PLC Kurt Salmon Associates, Inc ............. Kurt Salmon Associates, Inc. 

20072185 ......................... Thermo Fisher Scientific Inc ............. Priority Air Holdings Corp .................. Priority Air Holdings Corp. 

Transactions Granted Early Termination—09/26/2007 

20071496 ......................... Mylan Laboratories Inc ...................... E. Merck oHG .................................... EMD, Inc., Merck dura GmbH, Merck 

Genericos S.L., Merck Generics 

Belgium B.V.B.A., Merck Generics 

Group B.V. 

20072098 ......................... RF Micro Devices, Inc ....................... Sirenza Microdevices, Inc ................. Sirenza Microdevices, Inc. 

20072166 ......................... Knoll, Inc ............................................ Mr. John Edelman ............................. Teddy & Arthur Edelman, Limited 

20072172 ......................... Industrial Growth Partners III, L.P ..... Russell W. and Pamela C. Lane ....... Atlas Material Testing Technology, 

LLC 

20072174 ......................... New Mountain Lake Holdings, LLC .. U.S. Express Enterprises, Inc ........... U.S. Xpress Enterprises, Inc. 

20072188 ......................... Gildan Activewear Inc ....................... V.I. Prewett & Son, Inc. ..................... V.I. Prewett & Son, Inc. 

Transactions Granted Early Termination—09/27/2007 

20070861 ......................... FirstGroup plc .................................... Laidlaw International, Inc .................. Laidlaw International, Inc. 

20071415 ......................... Maruha Group Inc ............................. Nichiro Corporation ........................... Nichiro Corporation 

Transactions Granted Early Termination—09/28/2007 

20072179 ......................... BB&T Corporation ............................. Collateral Holdings, Ltd ..................... Collateral Management, LLC, Collateral Real Estate Capital, LLC 

20072184 ......................... Carlyle Europe Partners III, L.P ........ Sociedad General de Aguas de Barcelona, S.A. (‘‘Abgar’’).APPLUS Servicios Technologicos, 

S.L. 

20072186 ......................... Iconix Brand Group, Inc .................... Official Pillowtex, LLC ....................... Official Pillowtex, LLC 

20072187 ......................... Yahoo!, Inc ........................................ Zimbra, Inc ........................................ Zimbra, Inc. 

20072190 ......................... American Capital Strategies, Ltd ...... Wells Fargo & Company ................... Imperial Supplies LLC 

20072195 ......................... Warburg Pincus Private Equity IX, 

L.P.

Integra Telecom, Inc. ........................ Integra Telecom, Inc 

20072198 ......................... Pfingsten Executive QP Fund III, L.P Tropitone Furniture Co., Inc .............. Tropitone Furniture Co., Inc. 

20072201 ......................... ABRY Partners V, L.P ....................... EHR Holdings, LLC ........................... Executive Health Resources, Inc. 

20072204 ......................... GSCP Sigma (Lux) S.a.r.l ................. Sajjan Kumar Agarwal ....................... Gampak Products Corporation, 

Roemed Holdings, Inc., Semco 

Electric Private Limited, Sigma 

Electric Manufacturing Corporation, Ultratech Metals (India) Private Limited 

20072205 ......................... SECOM Co., LTD .............................. Gordon Crane .................................... Apple & Eve, LLC 

20072208 ......................... SECOM Co., LTD .............................. Weston Presidio Capital III, LP ......... Apple & Eve, LLC 

20072212 ......................... Francois Pinault ................................. United Retail Group, Inc. ................... United Retail Group, Inc 


rwilkins on PROD1PC63 with NOTICES
Federal Register / Vol. 72, No. 195 / Wednesday, October 10, 2007 / Notices 57579 

1 The comment must be accompanied by an 

explicit request for confidential treatment, 

including the factual and legal basis for the request, 

and must identify the specific portions of the 

comment to be withheld from the public record. 

The request will be granted or denied by the 

Commission’s General Counsel, consistent with 

applicable law and the public interest. See 

Commission Rule 4.9(c), 16 CFR 4.9(c). 

FOR FURTHER INFORMATION CONTACT: 

Sandra M. Peay, Contact Representative 

or Renee Hallman, Contact 

Representative. 

Federal Trade Commission, Premerger 

Notification Office, Bureau of 

Competition, Room H–303, Washington, 

DC 20580, (202) 326–3100. 

By direction of the Commission. 

Donald S. Clark, 

Secretary. 

[FR Doc. 07–4969 Filed 10–9–07; 8:45 am] 

BILLING CODE 6750–01–M 

FEDERAL TRADE COMMISSION 

[File No. 071 0164] 

Mylan Laboratories and E. Merck oHG; 

Analysis of Agreement Containing 

Consent Orders to Aid Public 

Comment 

AGENCY: Federal Trade Commission. 

ACTION: Proposed Consent Agreement. 

SUMMARY: The consent agreement in this 

matter settles alleged violations of 

federal law prohibiting unfair or 

deceptive acts or practices or unfair 

methods of competition. The attached 

Analysis to Aid Public Comment 

describes both the allegations in the 

draft complaint and the terms of the 

consent order—embodied in the consent 

agreement—that would settle these 

allegations. 

DATES: Comments must be received on 

or before October 27, 2007. 

ADDRESSES: Interested parties are 

invited to submit written comments. 

Comments should refer to ‘‘Mylan/ 

Merck, File No. 071 0164,’’ to facilitate 

the organization of comments. A 

comment filed in paper form should 

include this reference both in the text 

and on the envelope, and should be 

mailed or delivered to the following 

address: Federal Trade Commission/ 

Office of the Secretary, Room 135-H, 

600 Pennsylvania Avenue, NW., 

Washington, DC 20580. Comments 

containing confidential material must be 

filed in paper form, must be clearly 

labeled ‘‘Confidential,’’ and must 

comply with Commission Rule 4.9(c). 

16 CFR 4.9(c) (2005).1 The FTC is 

requesting that any comment filed in 

paper form be sent by courier or 

overnight service, if possible, because 

U.S. postal mail in the Washington area 

and at the Commission is subject to 

delay due to heightened security 

precautions. Comments that do not 

contain any nonpublic information may 

instead be filed in electronic form as 

part of or as an attachment to email 

messages directed to the following email box: consentagreement@ftc.gov. 

The FTC Act and other laws the 

Commission administers permit the 

collection of public comments to 

consider and use in this proceeding as 

appropriate. All timely and responsive 

public comments, whether filed in 

paper or electronic form, will be 

considered by the Commission, and will 

be available to the public on the FTC 

Web site, to the extent practicable, at 

http://www.ftc.gov. As a matter of 

discretion, the FTC makes every effort to 

remove home contact information for 

individuals from the public comments it 

receives before placing those 

commentson the FTC Web site. More 

information, including routine uses 

permitted by the Privacy Act, may be 

found in the FTC’s privacy policy, 

athttp://www.ftc.gov/ftc/privacy.htm. 

FOR FURTHER INFORMATION CONTACT: Kari 

A. Wallace (202) 326-3085, Bureau of 

Competition, Room NJ-5108, 600 

Pennsylvania Avenue, NW., 

Washington, DC 20580. 

SUPPLEMENTARY INFORMATION: Pursuant 

to section 6(f) of the Federal Trade 

Commission Act, 38 Stat. 721, 15 U.S.C. 

46(f), and § 2.34 of the Commission 

Rules of Practice, 16 CFR 2.34, notice is 

hereby given that the above-captioned 

consent agreement containing a consent 

order to cease and desist, having been 

filed with and accepted, subject to final 

approval, by the Commission, has been 

placed on the public record for a period 

of thirty (30) days. The following 

Analysis to Aid Public Comment 

describes the terms of the consent 

agreement, and the allegations in the 

complaint. An electronic copy of the 

full text of the consent agreement 

package can be obtained from the FTC 

Home Page (for September 27, 2007), on 

the World Wide Web, at http:// 

www.ftc.gov/os/2007/09/index.htm. A 

paper copy can be obtained from the 

FTC Public Reference Room, Room 130–

H, 600 Pennsylvania Avenue, NW., 

Washington, DC 20580, either in person 

or by calling (202) 326-2222. 

Public comments are invited, and may 

be filed with the Commission in either 

paper or electronic form. All comments 

should be filed as prescribed in the 

ADDRESSES section above, and must be 

received on or before the date specified 

in the DATES section. 

Analysis of Agreement Containing 

Consent Order to Aid Public Comment 

The Federal Trade Commission 

(‘‘Commission’’) has accepted, subject to 

final approval, an Agreement 

Containing Consent Orders (‘‘Consent 

Agreement’’) from Mylan Laboratories 

(‘‘Mylan’’) and E. Merck oHG (‘‘Merck’’) 

which is designed to remedy the 

anticompetitive effects of the 

acquisition of certain assets of Merck by 

Mylan. Under the terms of the proposed 

Consent Agreement, the companies 

would be required to assign and divest 

the Merck rights and assets necessary to 

manufacture and market generic: (1) 

Acebutolol hydrochloride capsules; (2) 

flecainide acetate tablets; (3) guanfacine 

hydrochloride tablets; (4) nicardipine 

hydrochloride capsules; and (5) sotalol 

hydrochloride AF tablets to Amneal 

Pharmaceuticals LLC (‘‘Amneal’’). 

The proposed Consent Agreement has 

been placed on the public record for 

thirty (30) days for receipt of comments 

by interested persons. Comments 

received during this period will become 

part of the public record. After thirty 

(30) days, the Commission will again 

review the proposed Consent Agreement 

and the comments received, and will 

decide whether it should withdraw from 

the proposed Consent Agreement, 

modify it, or make final the Decision 

and Order (‘‘Order’’). 

Pursuant to an Agreement and Plan of 

Merger executed on May 12 and 13, 

2007, Mylan proposes to acquire 

Merck’s generic subsidiary (‘‘Merck 

Generics’’) and all subsidiaries held 

directly or indirectly by Merck Generics, 

by acquiring 100 percent of the issued 

shares of those subsidies for 

approximately $6.6 billion. The 

Commission’s Complaint alleges that 

the proposed acquisition, if 

consummated, would violate section 7 

of the Clayton Act, as amended, 15 

U.S.C. § 18, and section 5 of the Federal 

Trade Commission Act, as amended, 15 

U.S.C. § 45, by lessening competition in 

the U.S. markets for the manufacture 

and sale of the following generic 

pharmaceutical products: (1) Acebutolol 

hydrochloride capsules; (2) flecainide 

acetate tablets; (3) guanfacine 

hydrochloride tablets; (4) nicardipine 

hydrochloride capsules; and (5) sotalol 

hydrochloride AF tablets (the 

‘‘Products’’). The proposed Consent 

Agreement will remedy the alleged 

violations by replacing the lost 

competition that would result from the 

acquisition in each of these markets. 

Mylan is a leading developer, 

manufacturer, marketer, and distributor 

of generic pharmaceutical drugs. 

Headquartered in Pennsylvania, Mylan 


rwilkins on PROD1PC63 with NOTICES